Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describe the characterization of a novel small molecule I...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Yvonne Grobben, Jos de Man, Antoon M. van Doornmalen, Michelle Muller, Nicole Willemsen-Seegers, Diep Vu-Pham, Winfried R. Mulder, Martine B. W. Prinsen, Joeri de Wit, Jan Gerard Sterrenburg, Freek van Cauter, Judith E. den Ouden, Anne M. van Altena, Leon F. Massuger, Joost C. M. Uitdehaag, Rogier C. Buijsman, Guido J. R. Zaman
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2021-01-01
Saila:	Frontiers in Immunology
Gaiak:	indoleamine 2,3-dioxygenase cancer immunotherapy immunosuppression tryptophan kynurenine syngeneic mouse model
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fimmu.2020.609490/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!